CLAIMS:

1. Use of an effective amount of minoxidil in the manufacture of an oral medicament for the treatment and prevention of alopecia areata in a subject wherein the effective amount of minoxidil is within the range from 0.1 mg to 0.49 mg, or from 0.1 mg to 0.4 mg, or from 0.15 mg to 0.3 mg, or from 0.2 mg to 0.28 mg, or is 0.25 mg, or is 0.24 mg, or is 0.1 mg daily.

2. The use according to claim 1, wherein the effective amount of oral minoxidil is 0.25 mg daily.

3. The use according to any one of claims 1 to 2, wherein the medicament further comprises spironolactone within the range of from 10 mg to 500 mg, or from 10 mg to 400 mg, or from 10 mg to 300 mg, or from 15 mg to 200 mg, or from 15 mg to 150 mg, or from 18 mg to 100 mg, or from 20 mg to 80 mg, or from 20 mg to 50 mg, or from 22 mg to 40 mg, or from 23 mg to 35 mg, or from 23 mg to 30 mg, or is 25 mg.

4. The use according to claim 3, wherein spironolactone is at a concentration of 25 mg.

5. The use according to any one of claims 1 to 4, where the medicament further comprises sodium chloride within the range of from 10 mg to 200 mg, from 15 mg to 150 mg, from 15 mg to 125 mg, from 20 mg to 100 mg, from 25 mg to 80 mg, from 30 mg to 70 mg, from 40 mg to 60 mg, from 45 mg to 55 mg, or is 50 mg, or is 20 mg.

6. The use according to claim 5, wherein sodium chloride is at a concentration of 20 mg.

7. The use according to any one of claims 1 to 6, wherein the medicament further comprises one or more of:

(i) finasteride within the range of from 0.1 mg to 1 mg;

(ii) dutasteride within the range of from 0.01 mg to 1 mg;

(iii) flutamide within the range of from 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from 1 mg to 100 mg;
(v) bicalutamide within the range of from 1 mg to 100 mg;
(vi) enzalutamide within the range of from 1 mg to 100 mg;
(vii) nilutamide within the range of from 1 mg to 100 mg;
(viii) drosperidone within the range of from 0.1 mg to 10 mg;
(ix) apalutamide within the range of from 1 mg to 100 mg; and/or
(x) buseralin within the range of from 0.1 mg to 10 mg.

8. Use of 0.25 mg minoxidil in the manufacture of a medicament for the treatment of alopecia areata in a subject.

9. The use of claim 8, wherein the medicament additionally comprises one or more of:

(i) spironolactone within the range of from 10 mg to 500 mg;
(ii) finasteride within the range of from 0.1 mg to 1 mg;
(iii) dutasteride within the range of from 0.01 mg to 1 mg;
(iv) flutamide within the range of from 10 mg to 500 mg;
(v) cyproterone acetate within the range of from 1 mg to 100 mg;
(vi) bicalutamide within the range of from 1 mg to 100 mg;
(vii) sodium chloride within the range of from 10 mg to 200 mg;
(viii) bicalutamide within the range of from 10 mg to 500 mg;
(iv) enzalutamide within the range of from 1 mg to 100 mg;
(x) nilutamide within the range of from 1 mg to 100 mg;
(xi) drosperidone within the range of from 0.1 mg to 10 mg;
(xii) apalutamide within the range of from 1 mg to 100 mg; and/or
(xiii) buseralin within the range of from 0.1 mg to 10 mg.

10. Use of an effective amount of minoxidil in the manufacture of an oral medicament for the treatment of alopecia areata in a subject wherein the effective amount of minoxidil is from 0.1 mg to 5 mg, or from 0.1 mg to 3 mg, or from 0.1 mg to 2.5 mg,

or from 0.1 mg to 2 mg, or from 0.1 mg to 1.5 mg, or from 0.1 mg to 1 mg, or from 0.1 mg to 0.75 mg, or from 0.1 mg to or 0.5 mg or from 0.1 mg to 0.25 mg daily.

11. The use according to claim 10, wherein the effective amount of minoxidil is 5 mg, or is 3 mg, or is 2.5 mg, or is 2 mg, or is 1.5 mg, or is 1 mg, or is 0.75 mg, or is 0.5 mg, or is 0.49 mg, or is 0.48 mg, or is 0.25 mg, or is 0.24 mg, or is 0.1 mg daily.

12. The use according to claim 10 or claim 11, wherein the effective amount of minoxidil is 2.5 mg, or is 1 mg, or is 0.5 mg.

13. The use according to any one of claims 10 to 12, wherein the medicament further comprises spironolactone within the range of from 10 mg to 500 mg, or from 10 mg to 400 mg, or from 10 mg to 300 mg, or from 15 mg to 200 mg, or from 15 mg to 150 mg, or from 18 mg to 100 mg, or from 20 mg to 80 mg, or from 20 mg to 50 mg, or from 22 mg to 40 mg, or from 23 mg to 35 mg, or from 23 mg to 30 mg, or is 25 mg.

14. The use according to claim 13, wherein spironolactone is at a concentration of 25 mg.

15. The use according to any one of claims 10 to 14, wherein the medicament further comprises sodium chloride within the range of from 10 mg to 200 mg, or from 15 mg to 150 mg, or from 15 mg to 125 mg, or from 20 mg to 100 mg, or from 25 mg to 80 mg, or from 30 mg to 70 mg, or from 40 mg to 60 mg, or from 45 mg to 55 mg.

16. The use according to claim 15, wherein sodium chloride is at a concentration of 20 mg.

17. The use according to any one of claims 10 to 16, wherein the medicament additionally comprises one or more of:

(i) finasteride within the range of from 0.1 mg to 1 mg;

(ii) dutasteride within the range of from 0.01 mg to 1 mg;

(iii) flutamide within the range of from 10 mg to 500 mg;

(iv) cyproterone acetate within the range of from 1 mg to 100 mg;

(v) bicalutamide within the range of from 1 mg to 100 mg;

(vi) enzalutamide within the range of from 1 mg to 100 mg;

(vii) nilutamide within the range of from 1 mg to 100 mg;

(viii) drosperidone within the range of from 0.1 mg to 10 mg;

(ix) apalutamide within the range of from 1 mg to 100 mg; and/or

(x) buseralin within the range of from 0.1 mg to 10 mg.

18. Use of 0.5 mg minoxidil in the manufacture of a medicament for the treatment of alopecia areata in a subject.